Nasonex (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal passages. The drug‑receptor complex then alters gene transcription, decreasing the production of inflammatory cytokines and chemokines, which reduces swelling and irritation of the nasal mucosa.

The specific dosing regimen for Nasonex is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and clinical response. Typically, one spray per nostril once daily is common, but the exact dose should follow the prescriber’s instructions.

Safety data for mometasone furoate in pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Nasonex product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasonex contains mometasone furoate, a high‑potency corticosteroid with a favorable local anti‑inflammatory profile. Compared with other nasal steroids such as fluticasone or budesonide, it offers similar efficacy in symptom control, but dosing frequency and potency may differ, allowing once‑daily administration for many patients.

Store Nasonex at ambient temperature, preferably below 25 °C, in its original packaging. Keep the container tightly closed and protect it from moisture and direct sunlight. Do not freeze the product, and keep it out of reach of children.

Nasonex is delivered as a metered‑dose nasal spray. The user should gently blow the nose, insert the tip into a nostril, close the opposite nostril, and press the actuator while inhaling gently through the nose. The recommended number of sprays per nostril is set by the prescriber.

Serious but rare risks include nasal septal perforation, suppression of the hypothalamic‑pituitary‑adrenal axis leading to systemic corticosteroid effects, and ocular complications such as increased intra‑ocular pressure or cataract formation. Patients should be monitored for these events, especially with long‑term use.

Nasonex should be avoided in individuals with a known hypersensitivity to mometasone furoate or any component of the formulation, and in patients with active untreated nasal or sinus infections. Caution is also advised for patients receiving systemic steroids or those with uncontrolled glaucoma.